Abstract: The present invention relates to antibodies that specifically bind to one or more of IL-4, IL-13, IL-33, TSLP, and p40. The present invention further relates to antibodies that bind to one of IL-4, IL-13, IL-33, or TSLP. The invention further relates to multispecific antibodies that specifically bind to IL-4 and IL-13, and at least one other target. The present invention relates to multispecific antibodies that bind IL-4, IL-13, and one of IL-33, TSLP, or p40. The present invention also pertains to related molecules, e.g. nucleic acids which encode such antibodies or multispecific antibodies, compositions, and related methods, e.g., methods for producing and purifying such antibodies and multispecific antibodies, and their use in diagnostics and therapeutics.

Abstract: Systems and techniques for authentication of impaired voices are described herein. A voice profile may be generated for a user. An audio stream may be received including an authentication voice of the user. It may be determined that the authentication voice does not match a first set of authentication criteria. The audio stream may be compared to a second set of authentication criteria. The user may be authenticated based on the comparison.

Abstract: An external catheter system is provided. The external catheter system includes an elongated sheath having an open upper end and an open lower end and a check valve. An inflatable ring is affixed about the open upper end. In some embodiments, the inflatable ring is removably securable to the open upper end of the elongated sheath. An inflation tube is in fluid communication with an interior volume of the inflatable ring. A syringe valve is affixed to a distal end of the inflation tube, wherein the syringe valve operably connects to a syringe. Upon depression of a plunger of the syringe, air is dispensed into the inflatable ring. The check valve has a generally conical shape and is inserted into the elongated sheath and is disposed before the drainage tube and sits within the elongated sheath.

Abstract: An external catheter system is provided. The system includes an elongated sheath having an open upper end and an open lower end. An inflatable ring is affixed about the open upper end. In some embodiments, the inflatable ring is removably securable to the open upper end of the elongated sheath. An inflation tube is in fluid communication with an interior volume of the inflatable ring. A syringe valve is affixed to a distal end of the inflation tube, wherein the syringe valve operably connects to a syringe. Upon depression of a plunger of the syringe, air is dispensed into the inflatable ring.

Abstract: An external catheter system is provided. The system includes an elongated sheath having an open upper end and an open lower end. An inflatable ring is affixed about the open upper end. In some embodiments, the inflatable ring is removably securable to the open upper end of the elongated sheath. An inflation tube is in fluid communication with an interior volume of the inflatable ring. A syringe valve is affixed to a distal end of the inflation tube, wherein the syringe valve operably connects to a syringe. Upon depression of a plunger of the syringe, air is dispensed into the inflatable ring.

Abstract: Data-persisting temporary virtual machine environments are described. A computing system enables a user to access a virtual machine and a virtual data store in a temporary virtual machine environment in response to receiving a user request to access the temporary virtual machine environment. The computing system stores data as virtual data store data in the virtual data store in response to receiving the data from the user. The computing system creates a copy of the virtual data store data if all users are signed off from use of the temporary virtual machine environment. The computing system deletes the virtual machine and the virtual data store. The computing system receives a request by a specific user to access the temporary virtual machine environment, and enables the specific user to access a recreated virtual machine and the copy of the virtual data store data.

Abstract: Data-persisting temporary virtual machine environments are described. A computing system enables a user to access a virtual machine and a virtual data store in a temporary virtual machine environment in response to receiving a user request to access the temporary virtual machine environment. The computing system stores data as virtual data store data in the virtual data store in response to receiving the data from the user. The computing system creates a copy of the virtual data store data if all users are signed off from use of the temporary virtual machine environment. The computing system deletes the virtual machine and the virtual data store. The computing system receives a request by a specific user to access the temporary virtual machine environment, and enables the specific user to access a recreated virtual machine and the copy of the virtual data store data.

Abstract: Techniques for managing a return request may be provided. For example, a user may want to return an item that the user received from an item provider via an electronic marketplace. The user can take a picture of the item and transmit the image to a computer that determines that the user would like to return the item. The computer may also determine that the item is returnable (e.g., was provided to the user within an allowable timeframe, satisfies a constraint for returning the item). The computer can initiate a return of the item. In some examples, the computer can also determine a convenient return location or the reason that the user is returning the item to the item provider.

Abstract: The invention discloses a previously unidentified subset of mammalian non-small cell lung carcinomas (NSCLC) in which platelet-derived growth factor receptor alpha (PDGFR?) is expressed and is driving the disease, and provides methods for identifying a mammalian NSCLC tumor that belongs to a subset of NSCLC tumors in which PDGFR? is expressed, and for identifying a NSCLC tumor that is likely to respond to a PDGFR?-inhibiting therapeutic. The invention also provides methods for inhibiting the progression of a mammalian NSCLC tumor in which PDGFR? is expressed, and for determining whether a compound inhibits the progression of a PDGFR?-expressing mammalian NSCLC tumor.

Abstract: The invention discloses a previously unidentified subset of mammalian non-small cell lung carcinomas (NSCLC) in which platelet-derived growth factor receptor alpha (PDGFR?) is expressed and is driving the disease, and provides methods for identifying a mammalian NSCLC tumor that belongs to a subset of NSCLC tumors in which PDGFR? is expressed, and for identifying a NSCLC tumor that is likely to respond to a PDGFR?-inhibiting therapeutic. The invention also provides methods for inhibiting the progression of a mammalian NSCLC tumor in which PDGFR? is expressed, and for determining whether a compound inhibits the progression of a PDGFR?-expressing mammalian NSCLC tumor.

Abstract: The invention discloses a previously unidentified subset of mammalian non-small cell lung carcinomas (NSCLC) in which platelet-derived growth factor receptor alpha (PDGFR?) is expressed and is driving the disease, and provides methods for identifying a mammalian NSCLC tumor that belongs to a subset of NSCLC tumors in which PDGFR? is expressed, and for identifying a NSCLC tumor that is likely to respond to a PDGFR?-inhibiting therapeutic. The invention also provides methods for inhibiting the progression of a mammalian NSCLC tumor in which PDGFR? is expressed, and for determining whether a compound inhibits the progression of a PDGFR?-expressing mammalian NSCLC tumor.

Abstract: The invention discloses novel phosphorylation sites identified in signal transduction proteins and pathways, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose.

Abstract: The invention discloses a previously unidentified subset of mammalian non-small cell lung carcinomas (NSCLC) in which platelet-derived growth factor receptor alpha (PDGFR?) is expressed and is driving the disease, and provides methods for identifying a mammalian NSCLC tumor that belongs to a subset of NSCLC tumors in which PDGFR? is expressed, and for identifying a NSCLC tumor that is likely to respond to a PDGFR?-inhibiting therapeutic. The invention also provides methods for inhibiting the progression of a mammalian NSCLC tumor in which PDGFR? is expressed, and for determining whether a compound inhibits the progression of a PDGFR?-expressing mammalian NSCLC tumor.

Abstract: The invention discloses 211 novel phosphorylation sites identified in signal transduction proteins and pathways underlying Anaplastic Large Cell Lymphoma (ALCL) involving the ALK-NPM translocation/fusion, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: Protein Kinases (including Receptor Tyrosine Kinases), Adaptor/Scaffold Proteins, Cellular Metabolism or Miscellaneous Enzymes, Oxidoreductases, Transcription Factors, Cytoskeletal Proteins, Translation Initiation Complexes, RNA Binding Proteins, Proteases, Acetyltransferases, G protein regulators/GTPases, Helicases, Apoptosis/Cell Cycle Regulation proteins, and Hydrolases.

Abstract: The invention discloses 168 novel phosphorylation sites identified in signal transduction proteins and pathways downstream of, and including, EGFR kinase, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: Actin Binding proteins, Adaptor/Scaffold proteins, Calcium-Binding Proteins, Cell Cycle Regulation proteins, Cytoskeletal proteins, DNA Binding and Replication Proteins, GTPase Activating proteins, Guanine Nucleotide Exchange Factor proteins, Lipid Kinases, Receptor Tyrosine Kinases, Receptor Tyrosine Kinase ligands, Protein Kinases, Receptor and Protein Phosphatases, Transcription Factor proteins, Tumor Suppressor proteins, and Vesicle proteins.

Abstract: The invention discloses 102 novel phosphorylation sites identified in signal transduction proteins and pathways downstream of c-Src kinase, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: Adaptor/Scaffold proteins, Actin Binding proteins, Cytoskeletal proteins, G protein/GTPase Activating protein/Guanine Nucleotide Exchange Factor proteins, Helicases, RNA Binding proteins, Transcription/Translation Factor or Initiation Complex proteins, Cellular Metabolism Enzymes, and Vesicle proteins.

Abstract: The invention discloses 214 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human carcinoma, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: Adaptor/Scaffold proteins, Cytoskeleton proteins, GTP Signaling proteins, Kinases, Metabolism proteins, Phosphatases/Phospho-diesterases/Proteases, Receptor proteins, RNA Processing proteins, Transcription proteins, Translation proteins, Transporter proteins, and Ubitquitin proteins, as well as other protein types.

Abstract: The invention discloses 95 novel phosphorylation sites identified in signal transduction proteins and pathways downstream of the T-cell receptor, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose.

Abstract: The invention discloses a previously unidentified subset of mammalian non-small cell lung carcinomas (NSCLC) in which platelet-derived growth factor receptor alpha (PDGFR?) is expressed and is driving the disease, and provides methods for identifying a mammalian NSCLC tumor that belongs to a subset of NSCLC tumors in which PDGFR? is expressed, and for identifying a NSCLC tumor that is likely to respond to a PDGFR?-inhibiting therapeutic. The invention also provides methods for inhibiting the progression of a mammalian NSCLC tumor in which PDGFR? is expressed, and for determining whether a compound inhibits the progression of a PDGFR?-expressing mammalian NSCLC tumor.

Abstract: The invention discloses nearly 288 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human Leukemia, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: Adaptor/Scaffold proteins, Cytoskeletal proteins, Cellular Metabolism enzymes, G Protein/GTPase Activating/Guanine Nucleotide Exchange Factor proteins, Immunoglobulin Superfamily proteins, Inhibitor proteins, Lipid Kinases, Nuclear DNA Repair/RNA Binding/Transcription proteins, Serine/Threonine Protein Kinases, Tyrosine Kinases, Protein Phosphatases, and Translation/Transporter proteins.